Sirios Capital Management LP Has Lifted By $25.16 Million Its Bank Amer (BAC) Stake; 0 Analysts Bullish Opexa Therapeutics (OPXA)

September 17, 2017 - By Vivian Currie

Sirios Capital Management LP increased Bank Amer Corp (BAC) stake by 21.26% reported in 2016Q4 SEC filing. Sirios Capital Management LP acquired 1.14M shares as Bank Amer Corp (BAC)’s stock declined 6.00%. The Sirios Capital Management LP holds 6.52M shares with $144.15 million value, up from 5.38M last quarter. Bank Amer Corp now has $257.22 billion valuation. The stock increased 0.58% or $0.14 on September 15, reaching $24.38. About 85.94M shares traded or 28.27% up from the average. Bank of America Corp (NYSE:BAC) has risen 58.64% since September 17, 2016 and is uptrending. It has outperformed by 41.94% the S&P500.

Among 2 analysts covering Opexa Therapeutics (NASDAQ:OPXA), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Opexa Therapeutics had 4 analyst reports since September 28, 2015 according to SRatingsIntel. On Friday, October 28 the stock rating was downgraded by Maxim Group to “Hold”. On Wednesday, November 4 the stock rating was initiated by Chardan Capital Markets with “Buy”. Chardan Capital Markets downgraded it to “Neutral” rating and $1 target in Friday, October 28 report. The firm has “Buy” rating by Maxim Group given on Monday, September 28. See Opexa Therapeutics Inc (NASDAQ:OPXA) latest ratings:

Among 29 analysts covering Bank of America (NYSE:BAC), 19 have Buy rating, 0 Sell and 10 Hold. Therefore 66% are positive. Bank of America had 79 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Buy” rating by Bernstein on Tuesday, September 1. The stock of Bank of America Corp (NYSE:BAC) has “Mkt Perform” rating given on Monday, August 24 by Bruyette & Woods”. As per Wednesday, December 21, the company rating was upgraded by Atlantic Securities. Renaissance Macro Securities LLC maintained Bank of America Corp (NYSE:BAC) rating on Sunday, July 23. Renaissance Macro Securities LLC has “Buy” rating and $2900 target. Oppenheimer maintained Bank of America Corp (NYSE:BAC) on Tuesday, July 18 with “Buy” rating. JP Morgan maintained Bank of America Corp (NYSE:BAC) rating on Thursday, April 7. JP Morgan has “Overweight” rating and $16 target. As per Wednesday, August 23, the company rating was maintained by BMO Capital Markets. The firm has “Market Perform” rating by Keefe Bruyette & Woods given on Monday, May 16. BMO Capital Markets maintained it with “Hold” rating and $2400 target in Wednesday, May 31 report. The rating was upgraded by CLSA on Friday, January 29 to “Outperform”.

Sirios Capital Management LP decreased Time Warner Inc (NYSE:TWX) stake by 66,563 shares to 1.36 million valued at $131.12M in 2016Q4. It also reduced Fedex Corp (NYSE:FDX) stake by 125,431 shares and now owns 447,506 shares. Radware Ltd (NASDAQ:RDWR) was reduced too.

Investors sentiment decreased to 1.12 in 2016 Q4. Its down 0.03, from 1.15 in 2016Q3. It dropped, as 62 investors sold BAC shares while 560 reduced holdings. 207 funds opened positions while 479 raised stakes. 6.48 billion shares or 6.26% more from 6.10 billion shares in 2016Q3 were reported. Canada Pension Plan Inv Board invested 3.66% in Bank of America Corp (NYSE:BAC). Seminole Mgmt holds 1.66M shares. Carroll Financial Associates reported 136,944 shares. Glenmede Tru Na holds 0.05% of its portfolio in Bank of America Corp (NYSE:BAC) for 447,834 shares. 2,140 are owned by Winfield Assocs. Clough Partners Lp has invested 3.31% of its portfolio in Bank of America Corp (NYSE:BAC). Tegean Cap Mgmt holds 4.07% of its portfolio in Bank of America Corp (NYSE:BAC) for 200,000 shares. Raymond James Trust Na accumulated 237,086 shares. Jacobs And Ca invested in 0.07% or 15,005 shares. Janney Montgomery Scott Limited stated it has 0.37% in Bank of America Corp (NYSE:BAC). Dowling Yahnke Limited Company holds 0.8% or 325,305 shares. Burney has 47,447 shares for 0.07% of their portfolio. 241,200 are held by Walleye Trading Limited Liability Corp. Hyman Charles D holds 48,604 shares. Nbt Commercial Bank N A reported 30,696 shares stake.

Opexa Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $7.81 million. The Firm is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). It currently has negative earnings. These therapies are based on its T-cell technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :